Three More Join Viatris In Dealing Out Of US Ozempic Patent Challenge
US Patent Trial and Appeal Board Told To Terminate Investigations Of Semaglutide Patent
Executive Summary
In the space of a few days, all four generics manufacturers that had successfully petitioned for a re-examination of a key patent shielding Novo Nordisk’s mega blockbuster Ozempic have reached settlement agreements terminating their challenges.